Myriad Genetics, Inc.
MYGN
Positions held
Your positionsMYGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $401.73M | Enterprise value | $497.03M | Trailing P/E | — | Forward P/E | -7.12 |
| PEG | 1.24 | Price / book | 1.32 | Beta | 1.64 | Dividend yield | 0.00% |
| Revenue growth | -10.5% | Earnings growth | — | Gross margin | 68.8% | Operating margin | -20.4% |
| Profit margin | -14.0% | ROE | -32.5% | ROA | -8.6% | Debt / equity | 0.69 |
| Current ratio | 2.21 | Free cash flow | $18.19M | Analyst recommendation | hold | Mean target | $4.05 |
| 52w high | $8.59 | 52w low | $2.74 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $191M | $200M | $210M | $206M | $213M | — |
| Op margin | -20.4% | -12.6% | -1.4% | -11.3% | -5.9% | — |
| Net income | -$43.2M | -$34.1M | -$7.9M | -$27.4M | -$331M | — |
| Gross margin | 66.6% | 68.7% | 70.0% | 69.9% | 71.2% | — |
| Gross profit | $127M | $138M | $147M | $144M | $152M | — |
| Operating income | -$38.9M | -$25.3M | -$3.0M | -$23.3M | -$12.5M | — |
- Revenue -5% vs prior quarter ($191M vs $200M).
- Gross margin 66.6% (was 68.7% prior quarter).
- Operating margin compressed to -20.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $825M | $838M | $753M | $678M | — |
| Op margin | -8.2% | -10.5% | -19.2% | -18.2% | — |
| Net income | -$366M | -$127M | -$263M | -$112M | — |
| Gross margin | 69.9% | 69.9% | 68.6% | 70.2% | — |
| Gross profit | $577M | $585M | $517M | $476M | — |
| Operating income | -$67.8M | -$88.0M | -$145M | -$124M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Sophia Genetics, Myriad Genetics Collaborate on Prostate Cancer Biomarker
2026-10-04 · Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split Targets
2026-10-03 · Why Is Myriad Genetics (MYGN) Stock Soaring Today
2026-10-02 · 1 Volatile Stock on Our Buy List and 2 We Question
2026-09-24 · 3 Reasons MYGN is Risky and 1 Stock to Buy Instead
2026-09-21 · Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
2026-09-18 · Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset
2026-09-17 · 1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
Price (daily)
Full chart · RSI · MACD · patterns